GLOPERBA®
Prophylaxis of Gout Flares
MarketedCommercial
Key Facts
About SCILEX
Scilex Holding Company (Nasdaq: SCLX) is a revenue-generating biopharmaceutical company dedicated to becoming a global leader in non-opioid pain management. Its strategy combines the commercialization of acquired, approved products like ZTlido®, Elyxyb®, and Gloperba® with the development of a proprietary pipeline, including the late-stage injectable candidate SEMDEXA™ for sciatica. Founded in 2013 and headquartered in Palo Alto, California, Scilex is positioned at the critical intersection of drug delivery innovation and the urgent societal need to address the opioid crisis.
View full company profileTherapeutic Areas
Other Prophylaxis of Gout Flares Drugs
| Drug | Company | Phase |
|---|---|---|
| Gloperba® (colchicine oral solution) | Scilex Holding | Commercial |